NovaBay Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . NovaBay Pharmaceuticals
NBY Stock  USD 7.39  0.64  9.48%   
NovaBay Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing NovaBay Pharmaceuticals' valuation are provided below:
Gross Profit
6.5 M
Profit Margin
0.3148
Market Capitalization
850.6 M
Enterprise Value Revenue
72.0381
Revenue
10.3 M
We have found one hundred twenty available fundamental ratios for NovaBay Pharmaceuticals, which can be analyzed and compared to other ratios and to its peers in the industry. All investors should make sure to check all of NovaBay Pharmaceuticals last-minute market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 936.1 K in 2026. Enterprise Value is likely to drop to about 510 K in 2026

NovaBay Pharmaceuticals Total Revenue

9.87 Million

Check NovaBay Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NovaBay Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 253.5 K, Interest Expense of 531.4 K or Other Operating Expenses of 17 M, as well as many indicators such as Price To Sales Ratio of 0.23, Dividend Yield of 0.0 or Days Sales Outstanding of 15.86. NovaBay financial statements analysis is a perfect complement when working with NovaBay Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with NovaBay Stock
Check out the analysis of NovaBay Pharmaceuticals Correlation against competitors.
For more information on how to buy NovaBay Stock please use our How to Invest in NovaBay Pharmaceuticals guide.

NovaBay Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets3.7 M3.9 M11 M
Pretty Stable
Other Assets470.5 K552 K471.5 K
Pretty Stable
Common Stock Shares Outstanding4.1 M3.9 M699.5 K
Slightly volatile
Liabilities And Stockholders Equity3.7 M3.9 M11 M
Pretty Stable
Other Stockholder Equity221.3 M210.8 M120.4 M
Slightly volatile
Total Liabilities7 M4.1 M6.4 M
Very volatile
Other Current Liabilities1.4 M884.4 K1.3 M
Very volatile
Total Current Liabilities4 M3.3 M3.6 M
Slightly volatile
Property Plant And Equipment Net1 M1.2 M824.6 K
Slightly volatile
Accounts Payable806.3 K716.5 K858.3 K
Very volatile
Cash367.6 K387 K5.5 M
Slightly volatile
Non Current Assets Total2 M1.7 M2 M
Slightly volatile
Cash And Short Term Investments367.6 K387 K6.3 M
Slightly volatile
Common Stock Total Equity263.6 K480.7 K311.4 K
Slightly volatile
Other Current Assets383.5 K403.6 K807.7 K
Pretty Stable
Property Plant And Equipment Gross1.2 M2 M1 M
Slightly volatile
Total Current Assets1.7 M1.7 M9.1 M
Slightly volatile
Common Stock53.5 K56.4 K214.5 K
Slightly volatile
Property Plant Equipment686.2 K907.2 K717 K
Slightly volatile
Other Liabilities12.2 M11.6 M6.3 M
Slightly volatile
Current Deferred Revenue417.2 K439.2 K1.2 M
Slightly volatile
Non Current Liabilities Total606.2 K638.1 K3 M
Slightly volatile
Short and Long Term Debt Total1.5 M1.9 M2.1 M
Very volatile
Non Currrent Assets Other3.3 K3.5 K258.9 K
Very volatile
Net Receivables332.6 K350.1 K1.4 M
Pretty Stable
Capital Surpluse130.9 M210.8 M117.9 M
Slightly volatile
Non Current Liabilities Other285.6 K300.6 K1.5 M
Slightly volatile
Short and Long Term Debt971.7 K508.5 K1.5 M
Slightly volatile
Cash And Equivalents367.6 K387 K6.4 M
Slightly volatile
Net Invested Capital367.6 K387 K3.7 M
Very volatile
Capital Stock60.1 K63.2 K544.7 K
Slightly volatile
Capital Lease Obligations1.3 M1.3 M1.3 M
Pretty Stable

NovaBay Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization253.5 K438.1 K242.4 K
Pretty Stable
Other Operating Expenses17 M18 M18.1 M
Pretty Stable
Research Development35.9 K37.8 K3 M
Slightly volatile
Total Operating Expenses15.1 M14.2 M15.9 M
Very volatile
Selling General Administrative6.8 M8.5 M6.5 M
Slightly volatile
Total Revenue9.9 M11.2 M9 M
Slightly volatile
Gross Profit8 M7.5 M6.8 M
Pretty Stable
Cost Of Revenue4.5 M3 M3.6 M
Very volatile
Selling And Marketing Expenses6.6 M3.6 M6.3 M
Pretty Stable
Interest Income104.9 K110.4 K1.9 M
Pretty Stable
Reconciled Depreciation238.7 K438.1 K181.1 K
Slightly volatile
Preferred Stock And Other Adjustments640 K720 K785.9 K
Slightly volatile

NovaBay Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow2.5 M2.6 M6.7 M
Slightly volatile
Depreciation264.8 K438.1 K244.5 K
Pretty Stable
Capital Expenditures5.1 K5.4 K83.2 K
Slightly volatile
Total Cash From Financing Activities1.6 M1.7 M7.3 M
Slightly volatile
End Period Cash Flow367.6 K387 K5.6 M
Slightly volatile
Stock Based Compensation126.5 K133.2 K847.5 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.230.2492.1363
Slightly volatile
Days Sales Outstanding15.8616.6953.0278
Slightly volatile
Stock Based Compensation To Revenue0.01650.01740.1589
Slightly volatile
Capex To Depreciation0.01720.01810.6189
Slightly volatile
Inventory Turnover2.183.882.4749
Slightly volatile
Days Of Inventory On Hand92.4497.31353
Slightly volatile
Payables Turnover3.164.773.4892
Slightly volatile
Sales General And Administrative To Revenue1.170.871.1405
Pretty Stable
Research And Ddevelopement To Revenue0.00470.00491.1259
Slightly volatile
Capex To Revenue7.0E-47.0E-40.0268
Slightly volatile
Cash Per Share0.140.15289
Slightly volatile
Days Payables Outstanding75.2879.244.1 K
Slightly volatile
Income Quality0.510.660.8035
Slightly volatile
Current Ratio0.740.783.1225
Slightly volatile
Receivables Turnover23.7622.639.5208
Slightly volatile
Capex Per Share0.00190.0025.102
Slightly volatile
Revenue Per Share3.153.31367
Pretty Stable
Interest Debt Per Share0.830.87105
Pretty Stable
Debt To Assets0.460.440.2928
Pretty Stable
Graham Number8891 K1.1 K
Slightly volatile
Operating Cycle108114282
Slightly volatile
Days Of Payables Outstanding75.2879.244.1 K
Slightly volatile
Ebt Per Ebit0.861.111.1082
Slightly volatile
Quick Ratio0.450.472.8591
Slightly volatile
Net Income Per E B T0.830.91.0285
Very volatile
Cash Ratio0.170.15121.9359
Slightly volatile
Days Of Inventory Outstanding92.4497.31353
Slightly volatile
Days Of Sales Outstanding15.8616.6953.0278
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.151.0292
Slightly volatile
Fixed Asset Turnover10.858.7314.8655
Very volatile
Debt Ratio0.460.440.2928
Pretty Stable
Price Sales Ratio0.230.2492.1363
Slightly volatile
Asset Turnover2.72.571.0634
Slightly volatile
Gross Profit Margin0.80.760.769
Slightly volatile

NovaBay Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap936.1 K985.3 K272.5 M
Slightly volatile

NovaBay Fundamental Market Drivers

NovaBay Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About NovaBay Pharmaceuticals Financial Statements

NovaBay Pharmaceuticals investors use historical fundamental indicators, such as NovaBay Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NovaBay Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue439.2 K417.2 K
Total Revenue11.2 M9.9 M
Cost Of Revenue3 M4.5 M
Stock Based Compensation To Revenue 0.02  0.02 
Sales General And Administrative To Revenue 0.87  1.17 
Revenue Per Share 3.31  3.15 
Ebit Per Revenue(0.54)(0.56)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
JBLJabil Circuit
MRKMerck Company
AMGNAmgen Inc

Additional Tools for NovaBay Stock Analysis

When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY